The startup develops therapeutic diagnostic technologies that utilize gastrointestinal microbiota transplants and bacteriophage research to create oral FMT capsules for patient treatment. This approach provides a convenient and cost-effective solution for patients requiring microbiome-based therapies without the risk of infection.
Funding
$17.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The rise of multidrug-resistant (MDR) bacteria poses a significant threat to global health, as traditional antimicrobial agents become ineffective. Current treatment options are limited, and the development of new drugs is slow and arduous, leaving patients vulnerable to life-threatening infections.
Solution
MicrobiotiX is developing bacteriophage-based therapies and microbiome-based treatments to combat MDR pathogens and other intractable diseases. The company has built a comprehensive bacteriophage library with over 300 lytic phages targeting gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli. MicrobiotiX also operates a microbiota bank, facilitating the development of microbiome-based therapies, including fecal microbiota transplantation (FMT) for conditions like C. difficile infections. The company's Custos platform analyzes pathogen-phage interactions to discover drug candidates and optimize manufacturing processes.
Target Audience
The primary target audience includes hospitals and research institutions seeking innovative solutions to combat multidrug-resistant bacterial infections, as well as patients with autoimmune diseases and other intractable conditions.
Features
- Bacteriophage library with 300+ lytic phages targeting major MDR gram-negative pathogens
- MP001: Lead pipeline candidate, a fixed-rate cocktail of 3 phages for acute pneumonia caused by MDR Pseudomonas aeruginosa
- Microbiota bank for FMT development, with strict risk factor screening based on international guidelines
- GMP facility for clinical trial material production and CDMO services
- Custos platform for cell banking, in-silico virulence optimization, microbiome modulation, and QbD-based CMC optimization
- Fecal microbiota available in liquid or oral capsule form